Print Friendly, PDF & Email

NCT/Study#

NA /

SY-1425-202

Phase II RARA(+) Actively Diagnosed/Untreated AML Study With Venetoclax/Azacitidine And SY-1425 With The Primary Objective To Characterize The Safety And Tolerability Of The Triplet Regimen.

DISEASE GROUP:
Leukemia
current phase:
Phase II
STUDY STATUS:
Active
Location:
Hackensack, NJ
For More information: